Tinzaparin
(SYRHIZPPCHMRIT-UHFFFAOYSA-N)
Structure
- SMILES
- [Sn+4]
- Molecular Formula:
- Sn++++
- Molecular Weight:
- 118.701
- Log P:
- -0.3808
- Hydrogen Bond Acceptor:
- 0
- Hydrogen Bond Donor:
- 0
- TPSA:
- 0
- CAS Number(s):
- 22537-50-4
Synonym(s)
1.
Tinzaparin
2.
2-Propenoic acid, 3-phenyl-
3.
Innohep
4.
Tinzaparin Sodium
5.
2 Propenoic acid, 3 phenyl
6.
3-phenyl- 2-Propenoic acid
External Link(s)
| MeSH | D000078222 |
| PubChem Compound | 4077523 |
| ChEBI | 30476 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Pulmonary Embolism | FAERS: 79 Canada Vigilance: 10 | Canada Vigilance US FAERS | |
| 2 | Drug exposure during pregnancy | FAERS: 61 | US FAERS | |
| 3 | Deep Vein Thrombosis | FAERS: 47 Canada Vigilance: 9 | Canada Vigilance US FAERS | |
| 4 | Drug ineffective | FAERS: 31 Canada Vigilance: 10 | Canada Vigilance US FAERS | |
| 5 | Heparin-induced thrombocytopenia | FAERS: 25 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 6 | Thrombosis | FAERS: 18 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 7 | Thrombosis in device | FAERS: 16 | US FAERS | |
| 8 | Medication Error | FAERS: 14 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Disease recurrence | FAERS: 13 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | Thrombocytopenia | FAERS: 13 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 11 | Overdose | FAERS: 11 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 12 | Thrombocytosis | FAERS: 11 | US FAERS | |
| 13 | Maternal exposure during pregnancy | FAERS: 10 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 14 | Incorrect drug administration duration | FAERS: 9 | US FAERS | |
| 15 | Cardiac Arrest | FAERS: 8 | US FAERS | |
| 16 | Arteriovenous fistula thrombosis | FAERS: 7 | US FAERS | |
| 17 | Asthenia | FAERS: 7 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 18 | Malaise | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 19 | Dizziness | FAERS: 5 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 20 | Drug dispensing error | FAERS: 5 | US FAERS | |
| 21 | Fatigue | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 22 | Hemiparesis | FAERS: 5 | US FAERS | |
| 23 | Hypersensitivity | FAERS: 5 | US FAERS | |
| 24 | Inappropriate schedule of drug administration | FAERS: 5 | US FAERS | |
| 25 | Nausea | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 26 | Phlebitis | FAERS: 5 | US FAERS | |
| 27 | Abdominal Pain | FAERS: 4 | US FAERS | |
| 28 | Accidental overdose | FAERS: 4 | US FAERS | |
| 29 | Cerebrovascular accident | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 30 | Chest Pain | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 31 | Drug administration error | FAERS: 4 | US FAERS | |
| 32 | Drug prescribing error | FAERS: 4 | US FAERS | |
| 33 | Feeling Cold | FAERS: 4 | US FAERS | |
| 34 | Gastritis | FAERS: 4 | US FAERS | |
| 35 | Incorrect dose administered | FAERS: 4 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 36 | Injection site pain | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 37 | Lip swelling | FAERS: 4 | US FAERS | |
| 38 | Mental status changes | FAERS: 4 | US FAERS | |
| 39 | Needle issue | FAERS: 4 | US FAERS | |
| 40 | Osteopenia | FAERS: 4 | US FAERS | |
| 41 | Osteoporosis | FAERS: 4 | US FAERS | |
| 42 | Post procedural complication | FAERS: 4 | US FAERS | |
| 43 | Pruritus | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 44 | Skin necrosis | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 45 | Vomiting | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 46 | Wrong technique in drug usage process | FAERS: 4 | US FAERS | |
| 47 | Arterial thrombosis | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 48 | Bronchopneumonia | FAERS: 3 | US FAERS | |
| 49 | Duodenal Ulcer | FAERS: 3 | US FAERS | |
| 50 | Duodenitis | FAERS: 3 | US FAERS | |
| 51 | Ecchymosis | FAERS: 3 | US FAERS | |
| 52 | Erythema | FAERS: 3 | US FAERS | |
| 53 | Headache | FAERS: 3 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 54 | Hepatitis | FAERS: 3 | US FAERS | |
| 55 | Injection site nodule | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 56 | Intentional drug misuse | FAERS: 3 | US FAERS | |
| 57 | No adverse event | FAERS: 3 | US FAERS | |
| 58 | Pain | FAERS: 3 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 59 | Pneumocystis jiroveci pneumonia | FAERS: 3 | US FAERS | |
| 60 | Procedural complication | FAERS: 3 | US FAERS | |
| 61 | Respiratory distress | FAERS: 3 | US FAERS | |
| 62 | Sepsis | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 63 | Sudden death | FAERS: 3 | US FAERS | |
| 64 | Vertigo | FAERS: 3 | US FAERS | |
| 65 | Acute Lung Injury | FAERS: 2 | US FAERS | |
| 66 | Anaphylactic shock | FAERS: 2 | US FAERS | |
| 67 | Angina Pectoris | FAERS: 2 | US FAERS | |
| 68 | Asthma | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 69 | Atrial Fibrillation | FAERS: 2 | US FAERS | |
| 70 | Blindness | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 71 | Bone pain | FAERS: 2 | US FAERS | |
| 72 | Bronchospasm | FAERS: 2 | US FAERS | |
| 73 | Cardiomegaly | FAERS: 2 | US FAERS | |
| 74 | Cauda Equina Syndrome | FAERS: 2 | US FAERS | |
| 75 | Congenital pyelocaliectasis | FAERS: 2 | US FAERS | |
| 76 | Congenital renal disorder | FAERS: 2 | US FAERS | |
| 77 | Deafness | FAERS: 2 | US FAERS | |
| 78 | Dehydration | FAERS: 2 | US FAERS | |
| 79 | Dental caries | FAERS: 2 | US FAERS | |
| 80 | Dermatitis acneiform | FAERS: 2 | US FAERS | |
| 81 | Disease Progression | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 82 | Embolism | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 83 | Fluid overload | FAERS: 2 | US FAERS | |
| 84 | Gestational Diabetes | FAERS: 2 | US FAERS | |
| 85 | Hydrocephalus | FAERS: 2 | US FAERS | |
| 86 | Hypoxia | FAERS: 2 | US FAERS | |
| 87 | Induration | FAERS: 2 | US FAERS | |
| 88 | Malignant neoplasm progression | FAERS: 2 | US FAERS | |
| 89 | Myocardial Infarction | FAERS: 2 | US FAERS | |
| 90 | Pleuritic pain | FAERS: 2 | US FAERS | |
| 91 | Postoperative wound complication | FAERS: 2 | US FAERS | |
| 92 | Pre-Eclampsia | FAERS: 2 | US FAERS | |
| 93 | Pregnancy | FAERS: 2 | US FAERS | |
| 94 | Product packaging quantity issue | FAERS: 2 | US FAERS | |
| 95 | Productive Cough | FAERS: 2 | US FAERS | |
| 96 | Psoriasis | FAERS: 2 | US FAERS | |
| 97 | Psychiatric symptom | FAERS: 2 | US FAERS | |
| 98 | Pyelocaliectasis | FAERS: 2 | US FAERS | |
| 99 | Respiratory Failure | FAERS: 2 | US FAERS | |
| 100 | Shock | FAERS: 2 | US FAERS | |
| 101 | Sinus Tachycardia | FAERS: 2 | US FAERS | |
| 102 | Skin lesion | FAERS: 2 | US FAERS | |
| 103 | Stillbirth | FAERS: 2 | US FAERS | |
| 104 | Suicide attempt | FAERS: 2 | US FAERS | |
| 105 | Tri-iodothyronine free increased | FAERS: 2 | US FAERS | |
| 106 | Urinary tract infection | FAERS: 2 | US FAERS | |
| 107 | Vasculitis | FAERS: 2 | US FAERS | |
| 108 | Venous Thrombosis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 109 | Visual disturbance | FAERS: 2 | US FAERS | |
| 110 | White blood cell count decreased | FAERS: 2 | US FAERS | |
| 111 | Wound Infection | FAERS: 2 | US FAERS | |
| 112 | Abdominal mass | FAERS: 1 | US FAERS | |
| 113 | Abdominal tenderness | FAERS: 1 | US FAERS | |
| 114 | Accidental exposure to product by child | FAERS: 1 | US FAERS | |
| 115 | Activated partial thromboplastin time shortened | FAERS: 1 | US FAERS | |
| 116 | Acute myocardial infarction | FAERS: 1 | US FAERS | |
| 117 | Adverse event | FAERS: 1 | US FAERS | |
| 118 | Alanine Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 119 | Anaplastic Oligodendroglioma | FAERS: 1 | US FAERS | |
| 120 | Angioedema | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 121 | Ankle Fracture | FAERS: 1 | US FAERS | |
| 122 | Anticoagulation drug level | FAERS: 1 | US FAERS | |
| 123 | Aphasia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 124 | Aplasia Cutis Congenita | FAERS: 1 | US FAERS | |
| 125 | Arterial Injury | FAERS: 1 | US FAERS | |
| 126 | Aspartate Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 127 | Atrial tachycardia | FAERS: 1 | US FAERS | |
| 128 | Blood antidiuretic hormone decreased | FAERS: 1 | US FAERS | |
| 129 | Blood blister | FAERS: 1 | US FAERS | |
| 130 | Blood lactate dehydrogenase increased | FAERS: 1 | US FAERS | |
| 131 | Bradycardia | FAERS: 1 | US FAERS | |
| 132 | Candida test positive | FAERS: 1 | US FAERS | |
| 133 | Candidiasis | FAERS: 1 | US FAERS | |
| 134 | Carotid Artery Thrombosis | FAERS: 1 | US FAERS | |
| 135 | Cell Death | FAERS: 1 | US FAERS | |
| 136 | Cerebral Infarction | FAERS: 1 | US FAERS | |
| 137 | Chemical peritonitis | FAERS: 1 | US FAERS | |
| 138 | Chest discomfort | FAERS: 1 | US FAERS | |
| 139 | Coagulation time shortened | FAERS: 1 | US FAERS | |
| 140 | Completed Suicide | FAERS: 1 | US FAERS | |
| 141 | Congenital cystic kidney disease | FAERS: 1 | US FAERS | |
| 142 | Creatinine renal clearance decreased | FAERS: 1 | US FAERS | |
| 143 | Creatinine renal clearance increased | FAERS: 1 | US FAERS | |
| 144 | Culture urine positive | FAERS: 1 | US FAERS | |
| 145 | Cyanosis | FAERS: 1 | US FAERS | |
| 146 | Dermatitis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 147 | Diabetic Amyotrophy | FAERS: 1 | US FAERS | |
| 148 | Disorientation | FAERS: 1 | US FAERS | |
| 149 | Drug ineffective for unapproved indication | FAERS: 1 | US FAERS | |
| 150 | Drug resistance | FAERS: 1 | US FAERS | |
| 151 | Dysarthria | FAERS: 1 | US FAERS | |
| 152 | Eclampsia | FAERS: 1 | US FAERS | |
| 153 | Electrocardiogram repolarisation abnormality | FAERS: 1 | US FAERS | |
| 154 | Epiploic appendagitis | FAERS: 1 | US FAERS | |
| 155 | Erosive Duodenitis | FAERS: 1 | US FAERS | |
| 156 | Exposure to contaminated device | FAERS: 1 | US FAERS | |
| 157 | Febrile Neutropenia | FAERS: 1 | US FAERS | |
| 158 | Febrile bone marrow aplasia | FAERS: 1 | US FAERS | |
| 159 | Foreign travel | FAERS: 1 | US FAERS | |
| 160 | Gamma-Glutamyltransferase Increased | FAERS: 1 | US FAERS | |
| 161 | Gastroduodenitis | FAERS: 1 | US FAERS | |
| 162 | Gastrointestinal infection | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 163 | General physical health deterioration | FAERS: 1 | US FAERS | |
| 164 | Growth retardation | FAERS: 1 | US FAERS | |
| 165 | HELLP Syndrome | FAERS: 1 | US FAERS | |
| 166 | Haematotoxicity | FAERS: 1 | US FAERS | |
| 167 | Hypochondriasis | FAERS: 1 | US FAERS | |
| 168 | Hypotension | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 169 | Hypoventilation | FAERS: 1 | US FAERS | |
| 170 | Ileus | FAERS: 1 | US FAERS | |
| 171 | Immediate post-injection reaction | FAERS: 1 | US FAERS | |
| 172 | Injection Site Reaction | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 173 | Injection site abscess | FAERS: 1 | US FAERS | |
| 174 | Injection site erythema | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 175 | Injection site necrosis | FAERS: 1 | US FAERS | |
| 176 | Injection site pruritus | FAERS: 1 | US FAERS | |
| 177 | Injection site vesicles | FAERS: 1 | US FAERS | |
| 178 | Intestinal Perforation | FAERS: 1 | US FAERS | |
| 179 | Local reaction | FAERS: 1 | US FAERS | |
| 180 | Lymphoma | FAERS: 1 | US FAERS | |
| 181 | Medical device complication | FAERS: 1 | US FAERS | |
| 182 | Memory impairment | FAERS: 1 | US FAERS | |
| 183 | Metastatic Renal Cell Carcinoma | FAERS: 1 | US FAERS | |
| 184 | Murphy's sign positive | FAERS: 1 | US FAERS | |
| 185 | Neonatal aspiration | FAERS: 1 | US FAERS | |
| 186 | Nephrectomy | FAERS: 1 | US FAERS | |
| 187 | Nephrocalcinosis | FAERS: 1 | US FAERS | |
| 188 | Neutropenia | FAERS: 1 | US FAERS | |
| 189 | No adverse effect | FAERS: 1 | US FAERS | |
| 190 | Nodule | FAERS: 1 | US FAERS | |
| 191 | Omental infarction | FAERS: 1 | US FAERS | |
| 192 | Palpitations | FAERS: 1 | US FAERS | |
| 193 | Phlebitis deep | FAERS: 1 | US FAERS | |
| 194 | Pilonidal cyst congenital | FAERS: 1 | US FAERS | |
| 195 | Plagiocephaly | FAERS: 1 | US FAERS | |
| 196 | Pneumonitis | FAERS: 1 | US FAERS | |
| 197 | Polydipsia | FAERS: 1 | US FAERS | |
| 198 | Polyneuropathy | FAERS: 1 | US FAERS | |
| 199 | Post procedural pulmonary embolism | FAERS: 1 | US FAERS | |
| 200 | Purpura | FAERS: 1 | US FAERS | |
| 201 | Rash erythematous | FAERS: 1 | US FAERS | |
| 202 | Reaction to drug excipients | FAERS: 1 | US FAERS | |
| 203 | Reaction to preservatives | FAERS: 1 | US FAERS | |
| 204 | Rhabdomyolysis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 205 | Scotoma | FAERS: 1 | US FAERS | |
| 206 | Secretion discharge | FAERS: 1 | US FAERS | |
| 207 | Septic Shock | FAERS: 1 | US FAERS | |
| 208 | Shunt occlusion | FAERS: 1 | US FAERS | |
| 209 | Skin Erosion | FAERS: 1 | US FAERS | |
| 210 | Skin Induration | FAERS: 1 | US FAERS | |
| 211 | Somnolence | FAERS: 1 | US FAERS | |
| 212 | Stress | FAERS: 1 | US FAERS | |
| 213 | Subdural Effusion | FAERS: 1 | US FAERS | |
| 214 | Swelling | FAERS: 1 | US FAERS | |
| 215 | Tachycardia | FAERS: 1 | US FAERS | |
| 216 | Talipes | FAERS: 1 | US FAERS | |
| 217 | Thoracotomy | FAERS: 1 | US FAERS | |
| 218 | Thrombophlebitis | FAERS: 1 | US FAERS | |
| 219 | Tobacco user | FAERS: 1 | US FAERS | |
| 220 | Tonsillitis | FAERS: 1 | US FAERS | |
| 221 | Transmission of an infectious agent via a medicinal product | FAERS: 1 | US FAERS | |
| 222 | Tremor | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 223 | Troponin increased | FAERS: 1 | US FAERS | |
| 224 | Tumour haemorrhage | FAERS: 1 | US FAERS | |
| 225 | Unresponsive to stimuli | FAERS: 1 | US FAERS | |
| 226 | Urethral perforation | FAERS: 1 | US FAERS | |
| 227 | Visual Impairment | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 228 | Wheezing | FAERS: 1 | US FAERS | |
| 229 | Wound sepsis | FAERS: 1 | US FAERS | |
| 230 | angiogram | FAERS: 1 | US FAERS | |
| 231 | jaundice | FAERS: 1 | US FAERS | |
| 232 | nervous system disorder | FAERS: 1 | US FAERS | |
| 233 | treatment failure | FAERS: 1 | US FAERS | |
| 234 | Accidental exposure to product | Canada Vigilance: 1 | Canada Vigilance | |
| 235 | Amnesia | Canada Vigilance: 1 | Canada Vigilance | |
| 236 | Anaphylactoid Reaction | Canada Vigilance: 1 | Canada Vigilance | |
| 237 | Antibody test abnormal | Canada Vigilance: 1 | Canada Vigilance | |
| 238 | Arterial bypass operation | Canada Vigilance: 1 | Canada Vigilance | |
| 239 | Arthralgia | Canada Vigilance: 1 | Canada Vigilance | |
| 240 | Ascites | Canada Vigilance: 1 | Canada Vigilance | |
| 241 | Back Pain | Canada Vigilance: 1 | Canada Vigilance | |
| 242 | Blood magnesium increased | Canada Vigilance: 1 | Canada Vigilance | |
| 243 | Blood sodium decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 244 | Carditis | Canada Vigilance: 1 | Canada Vigilance | |
| 245 | Chemical burns of eye | Canada Vigilance: 1 | Canada Vigilance | |
| 246 | Chills | Canada Vigilance: 1 | Canada Vigilance | |
| 247 | Choking | Canada Vigilance: 1 | Canada Vigilance | |
| 248 | Constipation | Canada Vigilance: 1 | Canada Vigilance | |
| 249 | Cystitis | Canada Vigilance: 1 | Canada Vigilance | |
| 250 | Device Failure | Canada Vigilance: 1 | Canada Vigilance | |
| 251 | Dystonia | Canada Vigilance: 1 | Canada Vigilance | |
| 252 | Epistaxis | Canada Vigilance: 2 | Canada Vigilance | |
| 253 | Eye irritation | Canada Vigilance: 1 | Canada Vigilance | |
| 254 | Flushing | Canada Vigilance: 1 | Canada Vigilance | |
| 255 | Hospice Care | Canada Vigilance: 1 | Canada Vigilance | |
| 256 | Inappropriate schedule of product administration | Canada Vigilance: 2 | Canada Vigilance | |
| 257 | Incorrect product administration duration | Canada Vigilance: 4 | Canada Vigilance | |
| 258 | Infection | Canada Vigilance: 1 | Canada Vigilance | |
| 259 | Injected limb mobility decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 260 | Injection site bruising | Canada Vigilance: 1 | Canada Vigilance | |
| 261 | Injection site hypersensitivity | Canada Vigilance: 1 | Canada Vigilance | |
| 262 | Injection site mass | Canada Vigilance: 1 | Canada Vigilance | |
| 263 | Joint injury | Canada Vigilance: 1 | Canada Vigilance | |
| 264 | Meconium abnormal | Canada Vigilance: 1 | Canada Vigilance | |
| 265 | Musculoskeletal stiffness | Canada Vigilance: 1 | Canada Vigilance | |
| 266 | Pelvic venous thrombosis | Canada Vigilance: 1 | Canada Vigilance | |
| 267 | Peripheral swelling | Canada Vigilance: 2 | Canada Vigilance | |
| 268 | Pneumonia | Canada Vigilance: 1 | Canada Vigilance | |
| 269 | Prescribed overdose | Canada Vigilance: 2 | Canada Vigilance | |
| 270 | Product administered to patient of inappropriate age | Canada Vigilance: 1 | Canada Vigilance | |
| 271 | Product dispensing error | Canada Vigilance: 1 | Canada Vigilance | |
| 272 | Product dose omission | Canada Vigilance: 1 | Canada Vigilance | |
| 273 | Product use in unapproved indication | Canada Vigilance: 5 | Canada Vigilance | |
| 274 | Rectal fissure | Canada Vigilance: 1 | Canada Vigilance | |
| 275 | Renal cancer metastatic | Canada Vigilance: 1 | Canada Vigilance | |
| 276 | Urticaria | Canada Vigilance: 1 | Canada Vigilance | |
| 277 | Weight decreased | Canada Vigilance: 4 | Canada Vigilance | |
| 278 | Wrong technique in product usage process | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120329
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.